A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

Trial Profile

A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms EXTEND
  • Sponsors Biogen
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 31 Aug 2019 to 25 Sep 2018.
    • 09 Apr 2018 Planned primary completion date changed from 31 Aug 2019 to 25 Sep 2018.
    • 02 Mar 2018 According to European Medicines Agency media release, the company has informed EMA of its decision to stop ongoing clinical studies with Zinbryta in the EU.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top